



Financial Tear Sheet

Corporate Profile

Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Primary IR Contact

Shawn Bevec
 Vice President Investor Relations
 Phone: 973-520-2900
Investor@QuestDiagnostics.com

Stock Performance

DGX (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$85.75
Change (%)	▲ 0.05 (0.06%)
Volume	1,486,535
52 Week Low	\$78.95
Market Cap	\$11,540,244,433
Rolling EPS	5.29
PE Ratio	16.2
Shares Outstanding	134,580,110
Data as of 04/18/19 4:00 p.m. ET	



EDGAROnline

Recent Press Releases

04/18/19

Quest Diagnostics Launches New Consumer-Initiated STD Tests Through QuestDirect™

04/11/19

Workforce Drug Testing Positivity Climbs to Highest Rate Since 2004, According to New Quest Diagnostics Analysis

04/04/19

Quest Diagnostics To Release First Quarter 2019 Financial Results On April 23

Upcoming Events


Date	Title
04/23/19	Q1 2019 Quest Diagnostics Earnings Release
04/23/19 8:30 a.m. ET	Q1 2019 Quest Diagnostics Earnings Conference Call

Recent SEC Filings

Filing Date	Form	Description
04/10/19	4	Statement of changes in beneficial ownership of securities
04/10/19	SC 13G/A	An amendment to the SC 13G filing
04/08/19	4	Statement of changes in beneficial ownership of securities
04/03/19	3	Initial filing by director officer or owner of more than ten percent.

Analyst Estimates / Ratings

Mean Recommendation: 2.6



Unable to fulfill request.

Board of Directors

Stephen H. Rusckowski

Chairman, President and Chief Executive Officer

Dan C. Stanzione, Ph.D.

Lead Independent Director

Jenne K. Britell, Ph.D.

Director

Vicky B. Gregg

Director

Jeffrey M. Leiden, M.D., Ph.D.

Director

Timothy L. Main

Director

Denise M. Morrison

Director

Gary M. Pfeiffer

Director

Timothy M. Ring

Director

Helen I. Torley, M.B. Ch. B., M.R.C.P.

Director

Gail R. Wilensky, Ph.D.

Director

Management Team

Stephen H. Rusckowski

Chairman, President and Chief Executive Officer

Everett Cunningham

Senior Vice President, Commercial

James E. Davis

Executive Vice President, General Diagnostics

Catherine T. Doherty

Senior Vice President and Group Executive – Clinical Franchise Solutions & Marketing

Carrie Eglinton Manner

Senior Vice President, Advanced Diagnostics

Mark J. Guinan

Executive Vice President and Chief Financial Officer

Cecilia McKenney

Senior Vice President, Chief Human Resources Officer

Michael E. Prevoznik

Senior Vice President and General Counsel

Gary D. Samuels

Vice President, Corporate Communications

Tim Sharpe

Vice President, Compliance

Dermot Shorten

Senior Vice President, Strategy, M&A and Ventures

Jay G. Wohlgemuth M.D.

Senior Vice President, R&D, Medical and Chief Medical Officer

Gabrielle Wolfson

Senior Vice President, Chief Information & Digital Officer

Ownership Summary

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
The Vanguard Group, Inc.	14,884,027	11.1	383,737	12/31/18
BlackRock Institutional Trust Company, N.A.	8,053,563	6.0	535,516	12/31/18
Macquarie Investment Management	7,698,210	5.7	998,318	12/31/18
State Street Global Advisors (US)	6,326,971	4.7	8,126	12/31/18
American Century Investment Management, Inc.	5,237,528	3.9	1,128,002	12/31/18
Fiduciary Management, Inc.	4,214,683	3.1	120,057	12/31/18
Victory Capital Management Inc.	2,811,037	2.1	135,312	12/31/18
Two Sigma Investments, LP	2,369,676	1.8	964,808	12/31/18
Geode Capital Management, L.L.C.	2,145,984	1.6	225,712	12/31/18
Marshall Wace LLP	2,051,729	1.5	-1,566,696	12/31/18